会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 84. 发明申请
    • Method and apparatus for recording and/or reproducing data and write-once information storage medium
    • 用于记录和/或再现数据和一次写入信息存储介质的方法和装置
    • US20050162989A1
    • 2005-07-28
    • US11019683
    • 2004-12-23
    • Sung-hee HwangJung-wan Ko
    • Sung-hee HwangJung-wan Ko
    • G11B5/09G11B7/085G11B7/24G11B20/10G11B20/12
    • G11B27/329G11B20/1217G11B27/105G11B2220/218G11B2220/2541
    • A method and apparatus for recording and/or reproducing data, and a write-once information storage medium. The write-once information storage medium includes at least one data area for recording user data and at least one recording management data (RMD) area for recording recording management data needed to use the at least one data area by dividing the at least one data area into a plurality of borders when recording the user data in a sequential recording mode and/or a random recording mode in the at least one data area. If RMD is recorded on the write-once information storage medium and the data area is divided into a plurality of borders and/or recording zones, data can be recorded on the write-once information storage medium in a sequential recording mode or a random recording mode. Therefore, the write-once information storage medium can be used with enhanced ease and efficiency.
    • 用于记录和/或再现数据的方法和装置,以及一次写入信息存储介质。 一次写入信息存储介质包括用于记录用户数据的至少一个数据区域和用于记录使用至少一个数据区域所需的记录管理数据的至少一个记录管理数据(RMD)区域,通过划分至少一个数据区域 在所述至少一个数据区域中以顺序记录模式和/或随机记录模式记录所述用户数据时,进入多个边界。 如果将RMD记录在一次写入信息存储介质上并且数据区域被划分为多个边界和/或记录区域,则数据可以以顺序记录模式或随机记录被记录在一次写入信息存储介质上 模式。 因此,可以更容易地和有效地使用一次写入信息存储介质。
    • 87. 发明授权
    • Pyrazole inhibitors of COX-2 and sEH
    • 吡唑类抑制剂COX-2和sEH
    • US09096532B2
    • 2015-08-04
    • US13993317
    • 2011-12-12
    • Bruce D. HammockSung Hee HwangKaren WagnerChristophe MorisseauAaron WeckslerGuodong Zhang
    • Bruce D. HammockSung Hee HwangKaren WagnerChristophe MorisseauAaron WeckslerGuodong Zhang
    • A61K31/635C07D231/10C07D231/12C07D231/40C07D231/14
    • C07D231/12C07D231/14C07D231/40
    • The present invention provides compounds and compositions, e.g., a series of compounds wherein a 1,5-biarylpyrazole group is conjugated to a urea group by a non-cleavable covalent chain, that are useful as dual COX-2/sEH inhibitors. The compounds disclosed herein have activity associated with the arachidonate cascade. The activity of these compounds was demonstrated using a lipopolysaccharide (LPS) induced model of pain in the rat. The compounds of the present invention demonstrated superior anti-allodynic activity as compared to the same dose of celecoxib, i.e., a COX-2 inhibitor, also as compared to the same dose of t-AUCB, i.e., a sEH inhibitor, and also as compared to the co-administered same dose of both celecoxib and t-AUCB. The dual inhibitors of the present invention demonstrate enhanced in vivo anti-allodynic activity in a nociceptive behavioral assay. In addition, the compounds of the present invention also demonstrated to have potent anti-angiogenic effects toward endothelial cells (HUVEC) and inhibit angiogenesis in vitro, ex vivo and in vivo. The dual inhibitors of the present invention also demonstrate anti-angiogenic effect to slow breast tumor growth in vivo.
    • 本发明提供化合物和组合物,例如一系列化合物,其中1,5-双芳基吡唑基团可通过不可裂解的共价链与脲基团缀合,其可用作双重COX-2 / sEH抑制剂。 本文公开的化合物具有与花生四烯酸级联相关的活性。 使用脂多糖(LPS)诱导的大鼠疼痛模型证明了这些化合物的活性。 与相同剂量的塞来昔布(即,COX-2抑制剂)相比,本发明的化合物与同样剂量的t-AUCB(即sEH抑制剂)相比,表现出优异的抗异常性疼痛活性,并且还作为 与联合给药相同剂量的塞来昔布和t-AUCB相比。 本发明的双重抑制剂在伤害性行为测定中表现出增强的体内抗异常性疼痛活性。 此外,本发明的化合物还证明对体内,体内和体内对内皮细胞(HUVEC)具有有效的抗血管生成作用并抑制血管生成。 本发明的双重抑制剂还表现出对血管内肿瘤生长缓慢的抗血管生成作用。